Venaxis, Inc. (NASDAQ:APPY) announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. Venaxis Inc. (NASDAQ:APPY) shares after opening at $2.10 moved to $2.10 on last trade day and at the end of the day closed at $2.03. Company price to sales ratio in past twelve months was calculated as 1107.87 and price to cash ratio as 3.59. Venaxis Inc. (NASDAQ:APPY) showed a negative weekly performance of -26.71%.
On February 14, 2014, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) completed its previously announced public offering (the “Offering”) of $200 million aggregate principal amount of the Company’s 2.50% Convertible Senior Notes due 2019 (the “Notes”), which includes $25 million principal amount of Notes issued pursuant to the full exercise of the over-allotment granted to the underwriters in the offering. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares fell -1.10% in last trading session and ended the day on $18.00. AMAG return on equity ratio is recorded as -5.60% and its return on assets is -3.70%. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) yearly performance is -19.82%.
Palatin Technologies (NYSE:PTN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Tuesday, ARN reports. The firm currently has a $1.50 target price on the stock. Zacks‘s price objective would suggest a potential upside of 21.95% from the company’s current price. Palatin Technologies, Inc. (NYSEMKT:PTN) shares moved up 0.81% in last trading session and was closed at $1.24, while trading in range of $1.22 – $1.30. Palatin Technologies, Inc. (NYSEMKT:PTN) year to date (YTD) performance is 69.86%.
Meridian Bioscience, Inc. (NASDAQ:VIVO) Cincinnati, Ohio has announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today’s healthcare market. Meridian Bioscience, Inc. (NASDAQ:VIVO) weekly performance is -3.56%. On last trading day company shares ended up $21.09. Meridian Bioscience, Inc. (NASDAQ:VIVO) distance from 50-day simple moving average (SMA50) is -2.62%. Analysts mean target price for the company is $23.14.